Identification

Logo pink
Are you a
new drug developer?
Contact us to learn more about our customized products and solutions.
Logo pink
Stay in the know!
As part of our commitment to providing the most up-to-date drug information, we will be releasing #DrugBankUpdates with our newly added curated drug pages.
#DrugBankUpdates
Name
Raltegravir
Accession Number
DB06817  (DB05355)
Type
Small Molecule
Groups
Approved
Description

Raltegravir is an antiretroviral drug produced by Merck & Co., used to treat HIV infection. It received approval by the U.S. Food and Drug Administration (FDA) on 12 October 2007, the first of a new class of HIV drugs, the integrase inhibitors, to receive such approval.

Structure
Thumb
Synonyms
  • Raltegravir
Product Ingredients
IngredientUNIICASInChI Key
Raltegravir potassium43Y000U234871038-72-1IFUKBHBISRAZTF-UHFFFAOYSA-M
Product Images
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
IsentressTablet, film coated400 mg/1OralDirect_Rx2019-08-13Not applicableUs
IsentressTablet, chewable100 mg/1OralMerck Sharp & Dohme Corp.2011-12-21Not applicableUs
IsentressTablet, film coated400 mg/1OralH.J. Harkins Company2017-07-31Not applicableUs
IsentressTablet, film coated400 mg/1OralPhysicians Total Care, Inc.2008-04-23Not applicableUs00006 0227 61 nlmimage10 a11dd0fe
IsentressTablet, chewable100 mgOralMerck Ltd.2013-02-11Not applicableCanada
IsentressTablet, film coated400 mg/1OralA-S Medication Solutions2007-10-12Not applicableUs50090 108520180913 8702 8koe6t
IsentressTablet, film coated400 mg/1OralMerck Sharp & Dohme Corp.2007-10-12Not applicableUs0006 022720180810 16125 vb986x
IsentressTablet, film coated400 mg/1OralAvera McKennan Hospital2015-04-032018-06-18Us
IsentressTablet, film coated400 mg/1OralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs53808 065020180907 15195 1c8c7xp
IsentressTablet, chewable25 mgOralMerck Ltd.2013-02-11Not applicableCanada
Additional Data Available
  • Application Number
    Application Number

    A unique ID assigned by the FDA when a product is submitted for approval by the labeller.

    Learn more
  • Product Code
    Product Code

    A governmentally-recognized ID which uniquely identifies the product within its regulatory market.

    Learn more
Categories
UNII
22VKV8053U
CAS number
518048-05-0
Weight
Average: 444.4163
Monoisotopic: 444.155746017
Chemical Formula
C20H21FN6O5
InChI Key
CZFFBEXEKNGXKS-UHFFFAOYSA-N
InChI
InChI=1S/C20H21FN6O5/c1-10-25-26-17(32-10)16(30)24-20(2,3)19-23-13(14(28)18(31)27(19)4)15(29)22-9-11-5-7-12(21)8-6-11/h5-8,28H,9H2,1-4H3,(H,22,29)(H,24,30)
IUPAC Name
N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-2-{2-[(5-methyl-1,3,4-oxadiazol-2-yl)formamido]propan-2-yl}-6-oxo-1,6-dihydropyrimidine-4-carboxamide
SMILES
CN1C(=O)C(O)=C(N=C1C(C)(C)NC(=O)C1=NN=C(C)O1)C(=O)NCC1=CC=C(F)C=C1

Pharmacology

Indication

For the treatment of HIV-1 infection in conjunction with other antiretrovirals.

Associated Conditions
Associated Therapies
Pharmacodynamics
Not Available
Mechanism of action

Raltegravir inhibits HIV integrase to prevent the viral genome being incorporated into the human genome. Raltegravir is primarily metabolized by glucuronidation.

TargetActionsOrganism
AIntegrase
inhibitor
Human immunodeficiency virus 1
Additional Data Available
Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Learn more
Additional Data Available
Contraindications

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.

Learn more
Additional Data Available
Blackbox Warnings

Structured data representing warnings from the black box section of drug labels. These warnings cover important and dangerous risks, contraindications, or adverse effects.

Learn more
Absorption

Absorbed from the gastrointestinal tract.

Volume of distribution

Approximately 83% bound to human plasma protein and is minimally distributed into red blood cells (blood-to-plasma partitioning ratio of 0.6).

Protein binding

83%

Metabolism

Hepatic (UGT1A1)

Route of elimination

Feces and urine

Half life

9 hours

Clearance

The major mechanism of clearance of raltegravir in humans is glucuronidation mediated by UGT1A1, the renal clearance of unchanged drug is a minor pathway of elimination of raltegravir (9% of total dose).

Toxicity
Not Available
Affected organisms
  • Human Immunodeficiency Virus
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
Acetylcysteine zincAcetylcysteine zinc can cause a decrease in the absorption of Raltegravir resulting in a reduced serum concentration and potentially a decrease in efficacy.
AcipimoxThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Acipimox.
AdenineThe metabolism of Raltegravir can be decreased when combined with Adenine.
Adenovirus type 7 vaccine liveThe therapeutic efficacy of Adenovirus type 7 vaccine live can be decreased when used in combination with Raltegravir.
Alendronic acidThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Alendronic acid is combined with Raltegravir.
AlmasilateThe serum concentration of Raltegravir can be decreased when it is combined with Almasilate.
AloglutamolThe serum concentration of Raltegravir can be decreased when it is combined with Aloglutamol.
AluminiumThe serum concentration of Raltegravir can be decreased when it is combined with Aluminium.
Aluminium acetoacetateThe serum concentration of Raltegravir can be decreased when it is combined with Aluminium acetoacetate.
Aluminium clofibrateThe risk or severity of myopathy, rhabdomyolysis, and myoglobinuria can be increased when Raltegravir is combined with Aluminium clofibrate.
Additional Data Available
  • Extended Description
    Extended Description

    Extended description of the mechanism of action and particular properties of each drug interaction.

    Learn more
  • Severity
    Severity

    A severity rating for each drug interaction, from minor to major.

    Learn more
  • Evidence Level
    Evidence Level

    A rating for the strength of the evidence supporting each drug interaction.

    Learn more
  • Action
    Action

    An effect category for each drug interaction. Know how this interaction affects the subject drug.

    Learn more
Food Interactions
Not Available

References

General References
  1. Nachman S, Zheng N, Acosta EP, Teppler H, Homony B, Graham B, Fenton T, Xu X, Wenning L, Spector SA, Frenkel LM, Alvero C, Worrell C, Handelsman E, Wiznia A: Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis. 2014 Feb;58(3):413-22. doi: 10.1093/cid/cit696. Epub 2013 Oct 21. [PubMed:24145879]
  2. Barau C, Furlan V, Yazdanpanah Y, Fagard C, Molina JM, Taburet AM, Barrail-Tran A: Characterization of binding of raltegravir to plasma proteins. Antimicrob Agents Chemother. 2013 Oct;57(10):5147-50. doi: 10.1128/AAC.00625-13. Epub 2013 Jul 15. [PubMed:23856784]
  3. Arora R, de Beauchene IC, Polanski J, Laine E, Tchertanov L: Raltegravir flexibility and its impact on recognition by the HIV-1 IN targets. J Mol Recognit. 2013 Sep;26(9):383-401. doi: 10.1002/jmr.2277. [PubMed:23836466]
  4. Eron JJ, Cooper DA, Steigbigel RT, Clotet B, Gatell JM, Kumar PN, Rockstroh JK, Schechter M, Markowitz M, Yeni P, Loutfy MR, Lazzarin A, Lennox JL, Strohmaier KM, Wan H, Barnard RJ, Nguyen BY, Teppler H: Efficacy and safety of raltegravir for treatment of HIV for 5 years in the BENCHMRK studies: final results of two randomised, placebo-controlled trials. Lancet Infect Dis. 2013 Jul;13(7):587-96. doi: 10.1016/S1473-3099(13)70093-8. Epub 2013 May 7. [PubMed:23664333]
  5. Winston A, Mallon PW, Boffito M: The clinical pharmacology of antiretrovirals in development. Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):447-58. [PubMed:16863445]
  6. O'Neal R: MK-0518 and GS-9137: two promising integrase inhibitors in the pipeline. BETA. 2006 Summer;18(4):13-6. [PubMed:17019786]
  7. James JS: Integrase inhibitor MK-0518: Merck opens expanded-access program. AIDS Treat News. 2006 Jul-Sep;(419):5. [PubMed:17096488]
  8. Markowitz M, Morales-Ramirez JO, Nguyen BY, Kovacs CM, Steigbigel RT, Cooper DA, Liporace R, Schwartz R, Isaacs R, Gilde LR, Wenning L, Zhao J, Teppler H: Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals. J Acquir Immune Defic Syndr. 2006 Dec 15;43(5):509-15. [PubMed:17133211]
  9. Colquitt AR, Pham PA: Expanded access drug profile: raltegravir (RAL, MK-0518). Hopkins HIV Rep. 2007 Jan;19(1):11-2. [PubMed:17569171]
  10. Authors unspecified: Raltegravir demonstrates potency. AIDS Patient Care STDS. 2007 Apr;21(4):288. [PubMed:17506141]
  11. Authors unspecified: Anti-HIV agents. Raltegravir--other issues. TreatmentUpdate. 2007 Feb;19(2):9-10. [PubMed:17447317]
  12. Authors unspecified: Anti-HIV agents. Integrase inhibitor raltegravir makes its mark. TreatmentUpdate. 2007 Feb;19(2):8-9. [PubMed:17447316]
  13. Cahn P, Sued O: Raltegravir: a new antiretroviral class for salvage therapy. Lancet. 2007 Apr 14;369(9569):1235-6. [PubMed:17434380]
External Links
KEGG Drug
D06676
PubChem Compound
54671008
PubChem Substance
175427095
ChemSpider
16445111
BindingDB
25351
ChEMBL
CHEMBL254316
HET
RLT
Drugs.com
Drugs.com Drug Page
Wikipedia
Raltegravir
ATC Codes
J05AR16 — Lamivudine and raltegravirJ05AX08 — Raltegravir
AHFS Codes
  • 08:18.08.12 — HIV Integrase Inhibitors
PDB Entries
3l2v / 3oya / 4mda / 4mdb
FDA label
Download (127 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0CompletedTreatmentHead and Neck Carcinoma1
0CompletedTreatmentHuman T-cell lymphotropic virus type I infection1
0CompletedTreatmentHuman T-cell lymphotropic virus type I infection / Tropical Spastic Paraparesis1
1Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailableDepression / Human Immunodeficiency Virus (HIV)1
1CompletedNot AvailableDepression / Human Immunodeficiency Virus (HIV) Infections / Mild Cognitive Impairment (MCI)1
1CompletedNot AvailableHealthy Volunteers2
1CompletedNot AvailableHigh Cholesterol / Human Immunodeficiency Virus (HIV)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV)1
1CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
1CompletedNot AvailablePharmacokinetics1
1CompletedBasic ScienceHealthy Volunteers1
1CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
1CompletedOtherHuman Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHealthy Volunteers4
1CompletedTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
1CompletedTreatmentHepatitis C Virus (HCV) Infection1
1CompletedTreatmentHepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV)5
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections12
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1) Infection1
1CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Tuberculosis Infection1
1Unknown StatusTreatmentHealthy Volunteers1
1, 2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
1, 2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
1, 2CompletedTreatmentAdult T-cell lymphomas/leukaemias1
1, 2CompletedTreatmentEvidence of Liver Transplantation / Hepatic Failure / Human Immunodeficiency Virus (HIV) Infections1
1, 2RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV)2
2Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Active Not RecruitingTreatmentVirus-HIV1
2CompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
2CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1)1
2CompletedTreatment2- HIV Infection1
2CompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections2
2CompletedTreatmentAntiretroviral Therapies / Human Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Infection(HIV)/Acquired Immunodeficiency Syndrome (AIDS)1
2CompletedTreatmentFibrosis, Liver / Hepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections9
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1)1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Lipodystrophies1
2CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
2CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection2
2CompletedTreatmentRelapsing Remitting Multiple Sclerosis (RRMS)1
2Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2Not Yet RecruitingTreatmentPrimary Biliary Cholangitis1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections2
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
2TerminatedTreatmentHuman Immunodeficiency Virus (HIV) / Lipohypertrophy1
2WithdrawnTreatmentHuman T-cell Leukemia Virus Type 1 Infection1
2, 3CompletedBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1
2, 3CompletedTreatment2- HIV Infection1
2, 3CompletedTreatmentAcute HIV Infection1
2, 3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
2, 3Not Yet RecruitingTreatmentSeverely Immunocompromised HIV Patients1
2, 3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) / Pregnancy1
3Active Not RecruitingBasic ScienceHuman Immunodeficiency Virus (HIV)1
3Active Not RecruitingTreatmentHIV-Associated neurocognitive disorder (HAND) / Human Immunodeficiency Virus (HIV) / Neurologic toxicity1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3Active Not RecruitingTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection / Tuberculosis Infection1
3CompletedTreatmentHuman Immunodeficiency Virus (HIV)4
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections17
3CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Hyperlipidemias / Hypertriglyceridemias1
3CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection4
3CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection / Renal Insufficiency,Chronic1
3RecruitingPreventionAIDS/HIV problem1
3RecruitingTreatmentAcquired Immune Deficiency Syndrome (AIDS)1
3RecruitingTreatmentHIV Seropositivity / HIV-1-infection / Human Immunodeficiency Virus (HIV) Infections2
3RecruitingTreatmentHuman Immunodeficiency Virus (HIV)1
3RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
3TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections4
3TerminatedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection / Treatment Resistant Disorders / Viral sepsis1
3Unknown StatusPreventionHuman Immunodeficiency Virus (HIV) / Infection NOS1
3WithdrawnTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection1
4Active Not RecruitingTreatmentChronic Hepatitis C Virus (HCV) Infection / Human Immunodeficiency Virus (HIV) Infections1
4Active Not RecruitingTreatmentChronic Infection With HIV1
4Active Not RecruitingTreatmentFatty Liver / HIV Seropositivity / Metabolic Syndromes1
4CompletedNot AvailableHealthy Volunteers1
4CompletedBasic ScienceHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedHealth Services ResearchHuman Immunodeficiency Virus (HIV)1
4CompletedPreventionHuman Immunodeficiency Virus (HIV)2
4CompletedPreventionHuman Immunodeficiency Virus (HIV) Infections3
4CompletedTreatmentAdverse Drug Reaction (ADR) / Human Immunodeficiency Virus (HIV) Infections / Quality of Life1
4CompletedTreatmentAging-related Inflammation in HIV-infected Patients1
4CompletedTreatmentCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV)1
4CompletedTreatmentCardiovascular Disease (CVD) / Human Immunodeficiency Virus (HIV) Infections / Inflammatory Reaction1
4CompletedTreatmentHCV Coinfection / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHIV Prevention / Human Immunodeficiency Virus (HIV) Infections1
4CompletedTreatmentHIV, Combination Therapy1
4CompletedTreatmentHealthy Volunteers1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV)4
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections13
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Human Immunodeficiency Virus Type 1 (HIV-1) Infection1
4CompletedTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections / Osteopenia / Osteoporosis1
4CompletedTreatmentHuman Immunodeficiency Virus Type 1 (HIV-1) Infection3
4CompletedTreatmentTumors, Solid1
4Enrolling by InvitationScreeningFatty Liver / Human Immunodeficiency Virus (HIV) / Nonalcoholic Steatohepatitis1
4Not Yet RecruitingOtherHuman Immunodeficiency Virus (HIV) Infections1
4Not Yet RecruitingPreventionHuman Immunodeficiency Virus (HIV)1
4Not Yet RecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHIV Associated Neurocognitive Disorders (HAND) / Human Immunodeficiency Virus (HIV)1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV)2
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections1
4TerminatedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Osteopenia1
4Unknown StatusBasic ScienceHuman Immunodeficiency Virus (HIV)1
4Unknown StatusTreatmentAcquired Immune Deficiency Syndrome (AIDS) / HIV-1 Adults Patients / Triple Class Failure1
4Unknown StatusTreatmentEndothelial Dysfunction / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV) Infections1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV)1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections3
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Tuberculosis Infection1
4Unknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
4WithdrawnTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
4WithdrawnTreatmentHepatitis C Viral Infection / Human Immunodeficiency Virus (HIV)1
Not AvailableActive Not RecruitingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableApproved for MarketingNot AvailableHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedNot AvailableAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV)1
Not AvailableCompletedNot AvailableHIV Integrase, HIV Protease / Integrase Inhibitors, HIV; HIV PROTEASE INHIB1
Not AvailableCompletedNot AvailableHealthy Volunteers2
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV)2
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus (HIV) Infections11
Not AvailableCompletedNot AvailableHuman Immunodeficiency Virus Type 1 (HIV-1) Infection1
Not AvailableCompletedPreventionHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedSupportive CareHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentAcquired Immune Deficiency Syndrome (AIDS) / Human Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableCompletedTreatmentAcute HIV Infection1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections6
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) Infections / Proteinuria1
Not AvailableCompletedTreatmentHuman Immunodeficiency Virus (HIV) / Virus Diseases1
Not AvailableRecruitingNot AvailableMinor Patient Treated by One or More Antiretroviral and for Which a Blood Test Has Been Performed1
Not AvailableRecruitingTreatment2- HIV Infection1
Not AvailableRecruitingTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableTerminatedTreatmentHuman Immunodeficiency Virus (HIV)1
Not AvailableUnknown StatusScreeningHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentHBV Coinfection / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) Infections / Sleep disorders and disturbances1
Not AvailableUnknown StatusTreatmentHuman Immunodeficiency Virus (HIV) / Human Immunodeficiency Virus (HIV) Infections1
Not AvailableWithdrawnBasic ScienceHuman Immunodeficiency Virus (HIV) Infections1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
Granule, for suspensionOral100 mg/1
TabletOral400 mg
Tablet, chewableOral100 mg/1
Tablet, chewableOral100 mg
Tablet, chewableOral25 mg
Tablet, chewableOral25 mg/1
Tablet, film coatedOral400 mg/1
Tablet, film coatedOral600 mg/1
TabletOral
PowderNot applicable1 kg/1kg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US7217713Yes2007-05-152023-04-21Us
US7435734Yes2008-10-142023-04-21Us
US7754731Yes2010-07-132029-09-11Us
US7169780Yes2007-01-302024-04-03Us
US7820660No2010-10-262023-04-25Us
US9649311Yes2017-05-162031-04-21Us
Additional Data Available
  • Filed On
    Filed On

    The date on which a patent was filed with the relevant government.

    Learn more

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
logP-0.39ChemAxon
pKa (Strongest Acidic)5.62ChemAxon
pKa (Strongest Basic)-1.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area150.02 Å2ChemAxon
Rotatable Bond Count6ChemAxon
Refractivity112.59 m3·mol-1ChemAxon
Polarizability42.47 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-qTof , PositiveLC-MS/MSNot Available
MS/MS Spectrum - , positiveLC-MS/MSsplash10-01ot-0417900000-7f0f52f17ac409473482
MS/MS Spectrum - , positiveLC-MS/MSsplash10-014i-0011900000-1f750fd89ed368c2519a

Taxonomy

Description
This compound belongs to the class of organic compounds known as pyrimidinecarboxylic acids and derivatives. These are compounds containing a pyrimidine ring which bears a carboxylic acid group (or a derivative thereof).
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Diazines
Sub Class
Pyrimidines and pyrimidine derivatives
Direct Parent
Pyrimidinecarboxylic acids and derivatives
Alternative Parents
2-heteroaryl carboxamides / Pyrimidones / Fluorobenzenes / Hydroxypyrimidines / Aryl fluorides / Hydropyrimidines / Vinylogous acids / 1,3,4-oxadiazoles / Heteroaromatic compounds / Secondary carboxylic acid amides
show 9 more
Substituents
Pyrimidine-6-carboxylic acid or derivatives / 2-heteroaryl carboxamide / Fluorobenzene / Hydroxypyrimidine / Halobenzene / Pyrimidone / Aryl fluoride / Aryl halide / Monocyclic benzene moiety / Hydropyrimidine
show 22 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organofluorine compound, pyrimidines, 1,2,4-oxadiazole, dicarboxylic acid amide (CHEBI:82960)

Targets

Kind
Protein
Organism
Human immunodeficiency virus 1
Pharmacological action
Yes
Actions
Inhibitor
General Function
Zinc ion binding
Specific Function
Not Available
Gene Name
pol
Uniprot ID
Q7ZJM1
Uniprot Name
Integrase
Molecular Weight
32226.645 Da
References
  1. Evering TH, Markowitz M: Raltegravir: an integrase inhibitor for HIV-1. Expert Opin Investig Drugs. 2008 Mar;17(3):413-22. doi: 10.1517/13543784.17.3.413 . [PubMed:18321239]
  2. Anker M, Corales RB: Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs. 2008 Jan;17(1):97-103. [PubMed:18095922]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid binding
Specific Function
UDPGT is of major importance in the conjugation and subsequent elimination of potentially toxic xenobiotics and endogenous compounds. This isoform glucuronidates bilirubin IX-alpha to form both the...
Gene Name
UGT1A1
Uniprot ID
P22309
Uniprot Name
UDP-glucuronosyltransferase 1-1
Molecular Weight
59590.91 Da
References
  1. Wenning LA, Petry AS, Kost JT, Jin B, Breidinger SA, DeLepeleire I, Carlini EJ, Young S, Rushmore T, Wagner F, Lunde NM, Bieberdorf F, Greenberg H, Stone JA, Wagner JA, Iwamoto M: Pharmacokinetics of raltegravir in individuals with UGT1A1 polymorphisms. Clin Pharmacol Ther. 2009 Jun;85(6):623-7. doi: 10.1038/clpt.2009.12. Epub 2009 Mar 11. [PubMed:19279563]
  2. Wenning LA, Hanley WD, Brainard DM, Petry AS, Ghosh K, Jin B, Mangin E, Marbury TC, Berg JK, Chodakewitz JA, Stone JA, Gottesdiener KM, Wagner JA, Iwamoto M: Effect of rifampin, a potent inducer of drug-metabolizing enzymes, on the pharmacokinetics of raltegravir. Antimicrob Agents Chemother. 2009 Jul;53(7):2852-6. doi: 10.1128/AAC.01468-08. Epub 2009 May 11. [PubMed:19433563]
  3. Anker M, Corales RB: Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection. Expert Opin Investig Drugs. 2008 Jan;17(1):97-103. [PubMed:18095922]

Drug created on September 14, 2010 10:21 / Updated on November 16, 2019 10:41